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Previewsin these highly chemoresistant subtypes
of AML with poor prognosis. Additional
studies will be required to elucidate a
possible mechanistic link between Mll3
function and the JQ1-mediated, and
potentially Myc-dependent, antiprolifera-
tive effect.
In summary, Chen et al. (2014) have
shown that Mll3 is a haploinsufficient
tumor suppressor on 7q that can act in
conjunction with heterozygous Nf1 dele-
tion (and possibly other mechanisms of
RAS pathway activation) and Tp53 defi-
ciency to induce an aggressive trans-
plantable AML in a murine model. Mll3
suppression leads to a partial differentia-
tion block at the level of HSC and MDS-
like cellular and molecular features.
Furthermore, Chen et al.’s mouse model
of Mll3 suppression-induced AML repre-
sents an interesting new tool for the pre-clinical evaluation and mechanistic study
of novel pathways and compounds that
may be effective for the treatment of 7/
7q- and possibly other types of chemo-
therapy-resistant AML.
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TGF-b signaling promotesmetastasis by controlling the expression of downstream target genes. In this issue
ofCancer Cell, Yuan and colleagues discover a novel TGF-b-induced lncRNA, lncRNA-ATB, which stimulates
EMT through sequestering miR-200s and facilitates colonization by stabilizing IL-11 mRNA, thus promoting
both early and late steps of cancer metastasis.The transforming growth factor-b (TGF-b)
pathway plays crucial roles during devel-
opment and homeostasis and exerts
strong antiproliferative effects on
normal and premalignant cells. However,
advanced-stage cancers often become
insensitive to the tumor-suppressive
actions of TGF-b. Instead, advanced
cancers benefit from TGF-b’s pro-
found metastasis-promoting effects,
such as epithelial-to-mesenchymal tran-
sition (EMT) induction, angiogenesis
promotion, altered extracellular matrix
deposition, immune suppression, and
increased metastatic colonization (Ikush-
ima and Miyazono, 2010; Massague´,2008). These prometastatic responses to
TGF-b are mediated by a variety of down-
stream effector proteins, including tran-
scription factors (e.g., AP-1, ID1, SNAIL,
SLUG, TWIST, and ZEB1/2), cytokines,
growth factors, and other ligands (e.g.,
ANGPTL4, PTHrP, IL-11, JAGGED1,
PDGF-B, CTGF, and VEGF), matrix pro-
teins and proteases (e.g., TNC, MMPs)
(Ikushima and Miyazono, 2010; Mas-
sague´, 2008), and a growing number of
microRNAs (miRNAs) (Butz et al., 2012).
In recent years, long noncoding RNAs
(lncRNAs), a new class of noncoding
RNAs longer than 200 nucleotides, were
recognized to regulate a wide variety ofphysiological and pathological processes
through diverse mechanisms. For
example, lncRNAs ANRIL and HOTAIR
promote tumor growth or metastasis by
recruiting chromatin-remodeling com-
plexes to alter gene transcription, while
tumor-suppressing lncRNA GAS5 and
tumor-promoting lncRNA HULC act
as decoys for glucocorticoid receptor
and miR-372, respectively (Gutschner
andDiederichs, 2012). Although the diver-
sity and abundance of lncRNAs seem to
rival that of mRNAs in any given cell
type, there is little understanding of
crucial lncRNAs functioning downstream
of the TGF-b pathway. In this issue ofl 25, May 12, 2014 ª2014 Elsevier Inc. 557
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Figure 1. LncRNA-ATB Acts Downstream of TGF-b to Promote Different Steps of Cancer
Metastasis
TGF-b signaling promotes metastasis by altering the expression of a variety of downstream genes,
including many protein-coding mRNAs, miRNAs, and, in the current study, a long noncoding RNA
lncRNA-ATB. TGF-b signaling induces lncRNA-ATB, which reinforces the prometastatic TGF-b response
via two distinct mechanisms. LncRNA-ATB competitively binds to miR-200s and sequesters them
away from their mRNA targets ZEB1 and ZEB2, which encode two key EMT-promoting transcription fac-
tors that repress the expression of E-cadherin and the miR-200s themselves, thus promoting EMT.
LncRNA-ATB also binds to and stabilizes IL-11 mRNA, thereby increasing autocrine IL-11-STAT3
signaling to enhance the survival and metastatic colonization of disseminated tumor cells in the lung
and liver. While ZEB1/2 and IL-11 are known to be activated by Smad-dependent pathways downstream
of TGF-b receptor activation, lncRNA-ATB is activated by a Smad-independent noncanonical pathway
that remains to be identified.
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PreviewsCancer Cell, Yuan et al. (2014) report a
novel TGF-b-induced lncRNA that am-
plifies the prometastatic effect of TGF-b
via two independent mechanisms.
Aiming to identify TGF-b-regulated
lncRNAs involved in EMT, Yuan et al.
(2014) profiled lncRNA expression in
human hepatocellular carcinoma (HCC)
cells after TGF-b treatment. The authors
focused their attention on lncRNAs that
might function as potential competing
endogenous RNAs (ceRNAs) against the
miR-200 family miRNAs, which are sup-
pressed by TGF-b signaling and are
potent inhibitors of EMT through targeting
of two master EMT transcription factors
ZEB1 and ZEB2 (Figure 1). One such
lncRNA, aptly named lncRNA-activated558 Cancer Cell 25, May 12, 2014 ª2014 Elsby TGF-b (lncRNA-ATB), stood out by vir-
tue of containing three predicted miR-200
binding sites. Binding of lncRNA-ATB by
miR-200s was confirmed by RNA
immunoprecipitation (RIP) of lncRNA-
ATB, luciferase assays, and anti-AGO2
RIP. LncRNA-ATB is nonpolyadenylated,
localizes primarily in the cytoplasm, and
has three close homologs in the human
genome. Notably, lncRNA-ATB is also up-
regulated by TGF-b in the MCF7 breast
cancer cell line and SMAD4-deficient
SW480 colorectal cancer cell line,
implying that lncRNA-ATB may be acti-
vated through the SMAD-independent,
noncanonical TGF-b pathway. LncRNA-
ATB increases ZEB1 and ZEB2 mRNA
and protein levels through competitivelyevier Inc.binding and sequestering miR-200s,
thereby inducing EMT (Figure 1). Remark-
ably, depletion of lncRNA-ATB is suffi-
cient to abolish TGF-b-induced EMT in
HCC cells, even though TGF-b is
known to strongly induce many other
EMT drivers, such as SNAIL, SLUG, and
TWIST. These findings suggest that
lncRNA-ATB may represent an essential
node in the EMT regulatory network.
While mutations in miR-200 binding
sites or miR-200 overexpression abol-
ished lncRNA-ATB’s function in stimu-
lating EMT, they only partially eliminated
the prometastatic effect of lncRNA-ATB,
suggesting that other mechanisms are
at play. The authors first tested the
role of lncRNA-ATB in different steps of
the metastatic cascade. While lncRNA-
ATB overexpression increases tumor
dissemination in a miR-200-dependent
manner, lncRNA-ATB promotes liver
and lung colonization of HCC cells inde-
pendent of miR-200s. Genome-wide RIP
revealed IL-11 mRNA as one of the top
transcripts bound by lncRNA-ATB. IL-
11 is a TGF-b target gene that has
been shown to promote bone metas-
tasis of breast cancer (Kang et al.,
2003) and liver colonization of colorectal
cancer by activating the prosurvival
GP130/STAT3 signaling pathway (Calon
et al., 2012). Yuan et al. (2014) showed
that lncRNA-ATB binds to and stabilizes
IL-11 mRNAs and stimulates autocrine
IL-11 production, thus triggering STAT3
signaling in tumor cells to promote colo-
nization (Figure 1).
LncRNA-ATB is upregulated in HCC
samples compared to paired noncan-
cerous hepatic tissues and significantly
correlates with liver cirrhosis, vascular
invasion, and reduced recurrence-free
and overall survival of HCC patients.
LncRNA-ATB levels are also significantly
higher in portal vein tumor thrombus, the
main route for intrahepatic metastasis of
HCC cells, compared to primary tumor
tissues. Furthermore, increased lncRNA-
ATB levels significantly correlate with
increased ZEB1/2 and IL-11mRNA levels
and decreased CDH1 (encoding for
E-cadherin). Collectively, these data high-
light strong clinical relevance and prog-
nostic value for lncRNA-ATB and suggest
its potential as a promising biomarker and
therapeutic target.
This exciting study revealed a novel
TGF-b-induced lncRNA that promotes
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Previewsboth early and late steps of HCC metas-
tasis by enhancing the prometastatic
effects of TGF-b signaling in EMT and
colonization. These findings also raised
important questions that warrant future
explorations. First, because lncRNA-
ATB is responsive to TGF-b induction
even in SMAD4-deficient cells, this indi-
cates that noncanonical SMAD-indepen-
dent pathways downstream of TGF-b
(Moustakas and Heldin, 2005) are
involved and that lncRNA-ATB might be
able to mediate the prometastatic func-
tion of TGF-b in the context of Smad
deficiency. Further studies are needed
to connect TGF-b signaling to lncRNA-
ATB activation and to investigate the po-
tential regulation of lncRNA-ATB by other
oncogenic signaling pathways that are
active in the tumor microenvironment.
On the other hand, among >20,000
lncRNAs in the human genome, other
lncRNAs (including those identified but
not explored further in the current study)
are also likely to be involved in mediating
tumor-suppressive or tumor-promoting
effects of TGF-b. The field remains
wide open to identify these TGF-
b-responsive lncRNAs and elucidate
their mechanisms of action.
It is also worth noting that the prometa-
static effects of lncRNA-ATB rely on
miR-200s and IL-11, whose expressions
were previously known to be regulated
by TGF-b through transcriptional
mechanisms independent of lncRNA-ATB. Thus, lncRNA-ATB functions by
enhancing the existing network of prome-
tastatic TGF-b signaling (Figure 1). It will
be of great interest to put this new link
into the tempo-spatial context of TGF-b
signaling dynamics during tumor progres-
sion. How are the levels of lncRNA-ATB
maintained in disseminated tumor cells
during colonization after the cells depart
from the TGF-b-rich primary tumor micro-
environment? Is lncRNA-ATB expression
maintained by a bistable control mecha-
nism just like the miR-200/ZEB double-
negative feedback loop, or perhaps
lncRNA-ATB has a long half-life? Is
lncRNA-ATB also involved in mediating
the paracrine signaling effect of TGF-b in
stromal cells during metastasis, as was
previously described for the production
of IL-11 from cancer-associated fibro-
blasts (Calon et al., 2012)?
Despite these questions, the strong
clinical significance of lncRNA-ATB in
HCC suggests its potential utility as a
therapeutic target. Soluble antisense
oligonucleotides against lncRNA-ATB or
other agents that block lncRNA-ATB’s
interactions with target miRNAs and
mRNAs may be developed to specifically
block the prometastatic branch of TGF-b
signaling (Wahlestedt, 2013). To avoid
potential detrimental side effects, it will
be essential to understand the normal
physiological function of lncRNA-ATB as
well as its three closely related homologs.
In this regard, it will also be important toCancer Celcharacterize the role of other miRNAs
and mRNAs that bind to lncRNA-ATB,
because they may also mediate lncRNA-
ATB’s function during development,
homeostatsis, and cancer progression.
Despite these challenges, the discovery
of lncRNA-ATB represents an exciting
step forward toward harnessing lncRNAs,
formerly among the ‘‘dark matters’’ of the
genome, for therapeutic intervention
against cancer.REFERENCES
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